Heidari Sayed Morteza, Rahimi Mojtaba, Soltani Hasanali, Hashemi Sayed J, Shabahang Shadi
Anaesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2014 Jan 27;3:64. doi: 10.4103/2277-9175.125845. eCollection 2014.
Postanesthetic shivering (PAS) is an accompanying part of general anesthesia with different unpleasant and stressful complications. Considering the importance of proper prevention of PAS in order to reduce its related adverse complications in patients undergoing surgery, in this study, we investigated the effect of orally administrated tramadol in the prevention of this common complication of general anesthesia.
In this prospective randomized double-blind clinical trial, 80 ASA I and II patients aged 15-70 years, scheduled for elective surgery under general anesthesia, were randomized to intervention (oral tramadol 50 mg) and placebo groups. PAS was evaluated during surgery and in the recovery room, and compared in the two study groups.
PAS was seen in 5 patients (12.5%) in the intervention group and 10 patients (25%) in the placebo group (P = 0.12). The prevalence of grade III and IV shivering was 7.5% (3/40) and 25% (10/40) in tramadol and placebo groups, respectively (P = 0.03).
The overall prevalence of PAS was not significantly different in the two study groups, but the higher grades of shivering which needed treatment were significantly lower in the tramadol group than in the placebo, and those patients who received tramadol experienced milder form of shivering. It is suggested that higher doses of tramadol would have better anti-shivering as well as analgesic effects. Studying different doses of tramadol would be helpful in this regard.
麻醉后寒战(PAS)是全身麻醉伴随出现的一部分,会引发不同的不适和应激并发症。鉴于正确预防PAS对于减少手术患者相关不良并发症的重要性,在本研究中,我们调查了口服曲马多在预防这种常见全身麻醉并发症方面的效果。
在这项前瞻性随机双盲临床试验中,80例年龄在15 - 70岁、计划接受全身麻醉下择期手术的美国麻醉医师协会(ASA)I级和II级患者被随机分为干预组(口服50毫克曲马多)和安慰剂组。在手术期间和恢复室对PAS进行评估,并在两个研究组之间进行比较。
干预组有5例患者(12.5%)出现PAS,安慰剂组有10例患者(25%)出现PAS(P = 0.12)。曲马多组和安慰剂组III级和IV级寒战的发生率分别为7.5%(3/40)和25%(10/40)(P = 0.03)。
两个研究组中PAS的总体发生率无显著差异,但需要治疗的较高等级寒战在曲马多组明显低于安慰剂组,且接受曲马多治疗的患者寒战程度较轻。建议更高剂量的曲马多可能具有更好的抗寒战以及镇痛效果。在这方面研究不同剂量的曲马多将有所帮助。